Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2366-2374

  Kaur, Manjinder ^a   Velmurugan, Balaiya ^a   Tyagi, Alpna ^a   Deep, Gagan ^a   Katiyar, Suchitra ^a   Agarwal, Chapla ^a,b   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; RETINOBLASTOMA PROTEIN; SILIBININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL CYCLE PROTEINS; CELL DEATH; COLORECTAL NEOPLASMS; HUMANS; MALE; MICE; MICE, NUDE; SILYMARIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68849113912     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0304     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Millikan KW, Staren ED, Doolas A. Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am 1997;77:27-48.
3. Ottaiano A, Franco R, Aiello Talamanca A, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006;12:2795-803.
4. Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 2008;15:1044-71.
5. Kumar N, Shibata D, Helm J, Coppola D, Malafa M. Green tea polyphenols in the prevention of colon cancer. Front Biosci 2007;12:2309-15.
6. Pierini R, Gee JM, Belshaw NJ, Johnson IT. Flavonoids and intestinal cancers. Br J Nutr 2008;99:ES53-9.
7. Tanaka T, Kohno H, Mori H. Chemoprevention of colon carcinogenesis by dietary non-nutritive compounds. Asian Pac J Cancer Prev 2001;2:165-77.
8. Wu H, Dai Q, Shrubsole MJ, et al. Fruit and vegetable intakes are associated with lower risk of colorectal adenomas. J Nutr 2008; Epub ahead of print.
9. Gescher A. Polyphenolic phytochemicals versus non-steroidal antiinflammatory drugs: which are better cancer chemopreventive agents? J Chemother 2004;16 Suppl 4:3-6.
10. McPartland JM, Vilgalys RJ, Cubeta MA. Mushroom poisoning. Am Fam Physician 1997;55:1797-1800, 1805-9, 1811-2.
11. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10:193-203.
12. Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 2007;6:130-45.
13. Ladas EJ, Kelly KM. Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? J Altern Complement Med 2003;9:411-6.
14. Velmurugan B, Singh RP, Tyagi A, Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res (Phila PA) 2008;1:376-84.
15. Agarwal C, Singh RP, Dhanalakshmi S, et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003;22:8271-82.
16. Kohno H, Tanaka T, Kawabata K, et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 2002;101:461-8.
17. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res 2007;143:58-65.
18. Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 2008;68:2043-50.
19. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
21. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004;116:221-34.
22. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
23. Rubin SM, Gall AL, Zheng N, Pavletich NP. Structure of the Rb C-terminal domain bound to E2F1-1: a mechanism for phosphorylation-induced E2F release. Cell 2005;123:1093-106.
24. Deep G, Agarwal R. New combination therapies with cell-cycle agents. Curr Opin Investig Drugs 2008;9:591-604.
25. 1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 1998;58:1920-9.
26. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 1997;75:337-49.
27. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007;6:2696-707.
28. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
29. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 1998;3:410-21.
30. Cheung CW, Taylor PJ, Kirkpatrick CM, et al. Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels. BJU Int 2007;100:438-44.
31. Singh RP, Tyagi A, Sharma G, Mohan S, Agarwal R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving downregulation of survivin. Clin Cancer Res 2008;14:300-8.
32. Singh RP, Deep G, Chittezhath M, et al. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 2006;98:846-55.
33. Flaig TW, Gustafson DL, Su LJ, et al. A phase Iand pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007;25:139-46.
34. Yang SH, Lin JK, Huang CJ, Chen WS, Li SY, Chiu JH. Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation. J Surg Res 2005;128:140-6.
35. Yang SH, Lin JK, Chen WS, Chiu JH. Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. J Surg Res 2003;113:133-8.
36. Zhu XL, Liang L, Ding YQ. Overexpression of FMNL2 is closely related to metastasis of colorectal cancer. Int J Colorectal Dis 2008;23:1041-7.
37. McLoughlin P, Roengvoraphoj M, Gissel C, Hescheler J, Certa U, Sachinidis A. Transcriptional responses to epigallocatechin-3 gallate in HT 29 colon carcinoma spheroids. Genes Cells 2004;9:661-9.
38. Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J 2003;17:1640-7.
39. Meeran SM, Katiyar SK. Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci 2008;13:2191-202.
40. 2-M transition by p53. Oncogene 2001;20:1803-15.
41. Tyagi A, Agarwal C, Agarwal R. The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells. Cell Cycle 2002;1:137-42.
42. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
43. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
44. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
45. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006;6:369-81.
46. Nickeleit I, Zender S, Kossatz U, Malek NP. p27kip1: a target for tumor therapies? Cell Div 2007;2:13.
47. Assoian RK, Yung Y. A reciprocal relationship between Rb and Skp2: implications for restriction point control, signal transduction to the cell cycle and cancer. Cell Cycle 2008;7:24-7.
48. Ziegler DS, Kung AL. Therapeutic targeting of apoptosis pathways in cancer. Curr Opin Oncol 2008;20:97-103.
49. Logue SE, Martin SJ. Caspase activation cascades in apoptosis. Biochem Soc Trans 2008;36:1-9.
50. Hoh C, Boocock D, Marczylo T, et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 2006;12:2944-50.